{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:48:49Z","timestamp":1759340929120},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,11,19]],"date-time":"2008-11-19T00:00:00Z","timestamp":1227052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with \u2018refractory anaemia\u2019 according to the World Health Organization (WHO). We treated 63 MDS patients [excluding refractory anaemia with excess blasts, type 2 (RAEB2)] with a previously tested combination of 13\u2010<jats:italic>cis<\/jats:italic>\u2010retinoic acid and dihydroxylated vitamin D3\u2003\u00b1\u20036\u2010thioguanine in addition to rEPO. Most patients were categorized as refractory cytopenia with multilineage dysplasia and RAEB1, with intermediate 1 International Prognostic Scoring System (IPSS) score; all had Hb &lt;95\u2003g\/l, and 70% required regular erythrocyte transfusions. Treatment was well tolerated, and erythroid response rate according to new International Working Group criteria was 60%: 50% in RAEB1 and 64% in non\u2010RAEB patients (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7383). Response rate was not affected by transfusion requirement (63%; 58% in untransfused), IPSS and WHO Prognostic Scoring System scores, and weekly rEPO dosage (30\u201350\u2003000\u2003U vs. 80\u2003000\u2003U). Median response duration was 16\u2003months. Median survival reached 14\u2003months for RAEB1 and 55\u2003months for non\u2010RAEB patients, with a significant difference in the latter between responders and non\u2010responders (median 82\u2003months vs. 44\u2003months; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7036). Our combined therapy, independent of rEPO dosage, achieved in patients with unfavourable response predictors, a rate of anaemia improvement comparable to the best obtained in lower risk patients by high\u2010dose rEPO.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07465.x","type":"journal-article","created":{"date-parts":[[2008,11,19]],"date-time":"2008-11-19T10:01:30Z","timestamp":1227088890000},"page":"342-349","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of a combination of human recombinant erythropoietin\u2003+\u200313\u2010<i>cis<\/i>\u2010retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low\/intermediate risk myelodysplastic syndromes"],"prefix":"10.1111","volume":"144","author":[{"given":"Dario","family":"Ferrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Darbesio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Giai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"Genuardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Maria","family":"Dellacasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sorasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-0044-6"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2252"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.12.4248"},{"key":"e_1_2_6_5_1","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson B.D.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80284-7"},{"key":"e_1_2_6_8_1","first-page":"127","volume-title":"Retinoids in Oncology","author":"Dimery I.W.","year":"1993"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(95)00156-5"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22343"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08909.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04153.x"},{"key":"e_1_2_6_15_1","first-page":"177","article-title":"Myelodysplastic syndromes: clinical features","volume":"33","author":"Hoffman W.K.","year":"1996","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01834360"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01085.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3872"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0372-z"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2004.1.297"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06070.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02016.x"},{"key":"e_1_2_6_25_1","first-page":"236","article-title":"Differentiation therapy in myelodysplastic syndromes","volume":"33","author":"Morosetti R.","year":"1996","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_26_1","first-page":"44","article-title":"Adding growth factors or interleukin 3 to erythropoietin has limited effects on anemia of transfusion\u2010dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone","volume":"86","author":"Musto P.","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05288.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.03.004"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-096370"},{"key":"e_1_2_6_31_1","first-page":"1058","article-title":"Erythropoietin plus granulocyte colony\u2010stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders","volume":"84","author":"Remacha A.F.","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2001.1.10"},{"key":"e_1_2_6_33_1","doi-asserted-by":"crossref","first-page":"2543a","DOI":"10.1182\/blood.V106.11.2543.2543","article-title":"Prognostic evaluation of myelodysplastic syndromes (MDS): analysis of deaths due to age\u2010related causes","volume":"106","author":"Salvi F.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200005000-00005"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0961-9"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1578"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh428"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi400"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07465.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07465.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:45:50Z","timestamp":1695919550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07465.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,16]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07465.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07465.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,16]]},"assertion":[{"value":"2009-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}